De SAFEHEART
- de Isla LP, Vallejo-Vaz AJ, Watts GF, Muñiz-Grijalvo O, Alonso R, Diaz-Diaz JL, Arroyo-Olivares R, Aguado R, Argueso R, Mauri M, Romero MJ, Álvarez-Baños P, Mañas D, Cepeda JM, Gonzalez-Bustos P, Casañas M, Michan A, Muñoz-Torrero JFS, Faedo C, Barba MA, Dieguez M, de Andrés R, Hernandez AM, Gonzalez-Estrada A, Padró T, Fuentes F, Badimon L, Mata P; SAFEHEART Investigators. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study. Lancet Diabetes Endocrinol. 2024 Sep;12(9):643-652. doi: 10.1016/S2213-8587(24)00192-X. Epub 2024 Aug 1.PMID: 39098315
- Bonet Estruch E, López-Lara MJ, Gutiérrez-Cortizo EN, Castaño López MA, Mata P, Romero-Jiménez MJ. Total Cholesterol Determination Accuracy in Dried Blood Spots. Diagnostics (Basel). 2024 Aug 29;14(17):1906. doi: 10.3390/diagnostics14171906.PMID: 39272691
- Tamehri Zadeh SS, Chan DC, Mata P, Watts GF. Coronary artery event-free or resilient familial hypercholesterolemia: what’s in a name? Curr Opin Endocrinol Diabetes Obes. 2024 Jul 5. doi: 10.1097/MED.0000000000000874. Online ahead of print.PMID: 38966915
- Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, de Andrés R, Fuentes F, Sánchez Muñoz-Torrero JF, Rubio P, Álvarez-Baños P, Mañas D, Suárez Gutierrez L, Saltijeral Cerezo A, Mata P; SAFEHEART Investigators. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circ Cardiovasc Imaging. 2024 Jan;17(1):e016206. doi: 10.1161/CIRCIMAGING.123.016206. Epub 2024 Jan 11.PMID: 38205656
- Alonso R, Arroyo-Olivares R, Díaz-Díaz JL, Fuentes-Jiménez F, Arrieta F, de Andrés R, Gonzalez-Bustos P, Argueso R, Martin-Ordiales M, Martinez-Faedo C, Illán F, Saenz P, Donate JM, Sanchez Muñoz-Torrero JF, Martinez-Hervas S, Mata P. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study. Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516. Online ahead of print.PMID: 38523000
- Escate R, Padró T, Pérez de Isla L, Fuentes F, Alonso R, Mata P, Badimon L. Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients. Atherosclerosis. 2024 Mar 8;392:117502. doi: 10.1016/j.atherosclerosis.2024.117502. Online ahead of print. PMID: 38513437
- Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, Sarkies MN, Al-Rasadi K, Blom DJ, Daccord M, de Ferranti SD, Folco E, Libby P, Mata P, Nawawi HM, Ramaswami U, Ray KK, Stefanutti C, Yamashita S, Pang J, Thompson GR, Santos RD. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023 Jun 15. doi: 10.1038/s41569-023-00892-0. Online ahead of print.PMID: 37322181
- Pérez de Isla L, Díaz-Díaz JL, Romero MJ, Muñiz-Grijalvo O, Mediavilla JD, Argüeso R, Sánchez Muñoz-Torrero JF, Rubio P, Álvarez-Baños P, Ponte P, Mañas D, Suárez Gutierrez L, Cepeda JM, Casañas M, Fuentes F, Guijarro C, Ángel Barba M, Saltijeral Cerezo A, Padró T, Mata P; SAFEHEART Study Group. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. Circulation. 2023 May 9;147(19):1436-1443. doi: 10.1161/CIRCULATIONAHA.122.062557. Epub 2023 Apr 3.PMID: 37009731
- Alonso R, Mata P. What are the controversies and appropriate guidance for cascade screening for lipoprotein(a)? Expert Rev Cardiovasc Ther. 2023 Apr;21(4):241-243. doi: 10.1080/14779072.2023.2192926. Epub 2023 Mar 30.PMID: 36995103.
- Mansilla-Rodríguez ME, Romero-Jimenez MJ, Rigabert Sánchez-Junco A, Gutierrez-Cortizo EN, Sánchez-Ramos JL, Mata P, Pang J, Watts GF. Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review. BMJ Open. 2023 Mar 29;13(3):e065551. doi: 10.1136/bmjopen-2022-065551.PMID: 36990476
- Alonso R, Arroyo-Olivares R, Muñiz-Grijalvo O, Díaz-Díaz DJL, Muñoz-Torrero JS, Romero MJ, de Andrés R, Zambón D, Mañas MD, Fuentes-Jiménez F, Aguado R, Alvarez-Baños P, Arrieta F, Gonzalez-Bustos P, Cepeda J, Martin-Ordiales M, Mosquera D, Michan A, de Isla LP, Argueso R, Mata P. Persistence with long-term PCSK9 inhibitors treatment and its effectiveness in Familial Hypercholesterolemia: data from the SAFEHEART study. Eur J Prev Cardiol. 2022 Nov 23:zwac277. doi: 10.1093/eurjpc/zwac277. PMID: 36416136
- Hegele R. ‘Keep on keeping on’: persistence with lipid-lowering treatment in familial hypercholesterolaemia. European Journal of Preventive Cardiology (2022) 00,1 –2. DOI: 10.1093/eurjpc/zwac297
- Pérez de Isla L, Alonso R, Argüeso R, Muñiz-Grijalvo O, Álvarez-Baños P, Badimón L, Watts GF, Mata P; SAFEHEART Investigators. Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients. J Clin Lipidol. 2022 Sep-Oct;16(5):733-736. doi: 10.1016/j.jacl.2022.07.007. Epub 2022 Jul 18. PMID: 35906178
- Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022. PMID: 35571022
- Al Dubayee M, Kayikcioglu M, van Lennep JR, Hergli N, Mata P. Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases. Adv Ther. 2022 Jun;39(6):3042-3057. doi: 10.1007/s12325-022-02131-3. Epub 2022 Apr 26. PMID: 35471728
- Alonso R, Argüeso R, Álvarez-Baños P, Muñiz-Grijalvo O, Diaz-Diaz JL, Mata P. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?. Curr Atheroscler Rep. 2022 Apr 7. DOI: 10.1007/s11883-022-01019-5
- Antoniazi L, Arroyo-Olivares R, Mata P, Santos RD. Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia. Curr Opin Lipidol. 2022 Apr 1;33(2):89-94. DOI: 10.1097/MOL.0000000000000813
- Pérez de Isla L, Watts GF, Muñiz-Grijalvo O, Díaz-Díaz JL, Alonso R, Zambón D, Fuentes-Jimenez F, Mauri M, Padró T, Vidal-Pardo JI, Barba MA, Ruiz-Pérez E, Michán A, Mediavilla JD, Hernandez AM, Romero-Jimenez MJ, Badimon L, Mata P; SAFEHEART Investigators. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort. Eur J Prev Cardiol. 2021 Dec 2:zwab185. https://doi.org/10.1093/eurjpc/zwab185
- Mata P, Alonso R, Pérez de Isla L, Badimón L. Dyslipidemia and aortic valve disease. Curr Opin Lipidol. 2021 Dec 1;32(6):349-354. DOI: 10.1097/MOL.0000000000000794
- EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021 Nov 6;398(10312):1713-1725. DOI: 10.1016/S0140-6736(21)01122-3
- Gallo A, Pérez de Isla L, Charrière S, Vimont A, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Moulin P, Bruckert E, Mata P, Béliard S; REFERCHOL and SAFEHEART Investigators. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. JACC Cardiovasc Imaging. 2021;14:2414-2424.
- Urtaran-Laresgoiti M, Nuño-Solinís R, Urizar E, Pérez de Isla L, Mata P, Leguina I. [The approach to hypercholesterolemia in health strategies and plans in Spain: present situation and future proposals]. An Sist Sanit Navar. 2021 Jun 18;0(0). doi: 10.23938/ASSN.0958. Online ahead of print. PMID: 34142984
- Garcia-Arguinzonis M, Diaz-Riera E, Peña E, Escate R, Juan-Babot O, Mata P, Badimon L, Padro T. Alternative C3 Complement System: Lipids and Atherosclerosis. Int J Mol Sci. 2021 May 12;22(10):5122. doi: 10.3390/ijms22105122. PMID: 34066088
- Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, de Andrés R, Arroyo-Olivares R, Fuentes-Jimenez F, Muñoz-Torrero JS, Cepeda J, Aguado R, Alvarez-Baños P, Casañas M, Dieguez M, Mañas MD, Rubio P, Argueso R, Arrieta F, Gonzalez-Bustos P, Perez-Isla L, Mata P; SAFEHEART investigators. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021 May 7:S1933-2874(21)00069-6. doi: 10.1016/j.jacl.2021.04.011. Online ahead of print. PMID: 34052174
- Antoniazzi L, Arroyo-Olivares R, Bittencourt MS, Tada MT, Lima I, Jannes CE, Krieger JE, Pereira AC, Quintana-Navarro G, Muñiz-Grijalvo O, Díaz-Díaz JL, Alonso R, Mata P, Santos RD. Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2021 Jun 30;31(7):2014-2022. doi: 10.1016/j.numecd.2021.04.006. Epub 2021 Apr 19. PMID: 34039501
- Sabatel-Pérez F, Sánchez-Prieto J, Becerra-Muñoz VM, Alonso-Briales JH, Mata P, Rodríguez-Padial L. Improving Familial Hypercholesterolemia Index Case Detection: Sequential Active Screening from Centralized Analytical Data. J Clin Med. 2021 Feb 13;10(4):749. doi: 10.3390/jcm10040749. PMID: 33668494
- Gutiérrez-Cortizo EN, Romero-Jiménez MJ, Mansilla Rodríguez ME, Díaz Santos MA, Caballero Granado FJ, Sánchez Ruiz-Granados E, Sánchez Ramos JL, Mata P. Detection of Familial Hypercholesterolemia through centralized analytical data. HF HUELVA DETECTA Program. Endocrinol Diabetes Nutr (Engl Ed). 2021 Feb 27:S2530-0164(21)00041-0. doi: 10.1016/j.endinu.2020.09.011. Online ahead of print. PMID: 33653676
- Pérez de Isla L, Watts GF, Alonso R, Díaz-Díaz JL, Muñiz-Grijalvo O, Zambón D, Fuentes F, de Andrés R, Padró T, López-Miranda J, Mata P. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J. 2021 Jun 7;42(22):2201-2211. doi: 10.1093/eurheartj/ehaa1066. PMID: 33437997
- Pérez de Isla L, Alonso R, Gómez de Diego JJ, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Miramontes JP, Fuentes F, de Andrés R, Werenitzky J, Padró T, Saltijeral A, Mata P; SAFEHEART investigators. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study. Atherosclerosis. 2021 Jan;317:52-58. doi: 10.1016/j.atherosclerosis.2020.11.012. Epub 2020 Nov 18. PMID: 33261814
- Bayona A, Arrieta F, Rodríguez-Jiménez C, Cerrato F, Rodríguez-Nóvoa S, Fernández-Lucas M, Gómez-Coronado D, Mata P. Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report. Medicine (Baltimore). 2020 Aug 21;99(34):e21754. doi: 10.1097/MD.0000000000021754. PMID: 32846800
- Alves AC, Alonso R, Diaz-Diaz JL, Medeiros AM, Jannes CE, Merchan A, Vasques-Cardenas NA, Cuevas A, Chacra AP, Krieger JE, Arroyo R, Arrieta F, Schreier L, Corral P, Bañares VG, Araujo MB, Bustos P, Asenjo S, Stoll M, Dell’Oca N, Reyes M, Ressia A, Campo R, Magaña-Torres MT, Metha R, Aguilar-Salinas CA, Ceballos-Macias JJ, Morales ÁJR, Mata P, Bourbon M, Santos RD. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. Arterioscler Thromb Vasc Biol. 2020 Aug 6:ATVBAHA120313722. doi: 10.1161/ATVBAHA.120.313722. Online ahead of print. PMID: 32757650
- Pérez de Isla L, Arroyo-Olivares R, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Fuentes F, Mata N, Piedecausa M, Mañas MD, Sánchez Muñoz-Torrero JF, Miramontes-González JP, de Andrés R, Mauri M, Aguado R, Brea Á, Cepeda JM, Vidal-Pardo JI, Martínez-Faedo C, Barba MÁ, Argüeso R, Ruiz-Pérez E, Michán A, Arrieta F, Riestra Fernández M, Pérez L, Pinilla JM, Díaz-Soto G, Pintó X, Padró T, Badimón L, Mata P; SAFEHEART researchers. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Rev Esp Cardiol (Engl Ed). 2020 Mar 20:S1885-5857(20)30065-7. doi: 10.1016/j.rec.2019.10.028. Online ahead of print. PMID: 32201274
- Escate R, Padró T, Suades R, Camino S, Muñiz O, Diaz-Diaz JL, Sionis A, Mata P, Badimon L. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolemia patients. Cardiovasc Res. 2020 Feb 15:cvaa039. doi: 10.1093/cvr/cvaa039. Online ahead of print. PMID: 32061123
- Alonso R, Perez de Isla L, Muñiz-Grijalvo O, Mata P. Barriers to Early Diagnosis and Treatment of Familial Hypercholesterolemia: Current Perspectives on Improving Patient Care. Vasc Health Risk Manag. 2020 Jan 9;16:11-25. doi: 10.2147/VHRM.S192401. eCollection 2020. PMID: 32021224
- Watts GF, Gidding SS, Mata P, Pang J, Sullivan DR, Yamashita S, Raal FJ, Santos RD, Ray KK. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020 Jun;17(6):360-377. doi: 10.1038/s41569-019-0325-8. Epub 2020 Jan 23. PMID: 31974482
- Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, Alonso R, Al-Rasadi K, Badimon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Cillíková K, Corral P, Cuevas R, Defesche JC, Descamps OS, de Ferranti S, Eiselé JL, Elikir G, Folco E, Freiberger T, Fuggetta F, Gaspar IM, Gesztes ÁG, Grošelj U, Hamilton-Craig I, Hanauer-Mader G, Harada-Shiba M, Hastings G, Hovingh GK, Izar MC, Jamison A, Karlsson GN, Kayikçioglu M, Koob S, Koseki M, Lane S, Lima-Martinez MM, López G, Martinez TL, Marais D, Marion L, Mata P, Maurina I, Maxwell D, Mehta R, Mensah GA, Miserez AR, Neely D, Nicholls SJ, Nohara A, Nordestgaard BG, Ose L, Pallidis A, Pang J, Payne J, Peterson AL, Popescu MP, Puri R, Ray KK, Reda A, Sampietro T, Santos RD, Schalkers I, Schreier L, Shapiro MD, Sijbrands E, Soffer D, Stefanutti C, Stoll M, Sy RG, Tamayo ML, Tilney MK, Tokgözoglu L, Tomlinson B, Vallejo-Vaz AJ, Vazquez-Cárdenas A, de Luca PV, Wald DS, Watts GF, Wenger NK, Wolf M, Wood D, Zegerius A, Gaziano TA, Gidding SS. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020 Feb 1;5(2):217-229. doi: 10.1001/jamacardio.2019.5173.
PMID: 31895433 - Pérez de Isla L, Arroyo-Olivares R, Muñiz-Grijalvo O, Diaz-Díaz JL, Zambón D, Fuentes F, Sánchez Muñoz-Torrero JF, Mediavilla JD, González-Estrada A, Miramontes-González JP, de Andrés R, Mauri M, Mosquera D, Cepeda JM, Suárez L, Barba-Romero MÁ, Argüeso R, Álvarez-Baños P, Michán A, Romero-Jiménez MJ, García-Cruces J, Padró T, Alonso R, Mata P. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. J Clin Lipidol. 2019 Oct 11. pii: S1933-2874(19)30289-2. doi: 10.1016/j.jacl.2019.10.005. [Epub ahead of print]. PMID: 1706904
- Antoniazzi L, Arroyo-Olivares R, Bittencourt MS, Tada MT, Lima I, Jannes CE, Krieger JE, Pereira AC, Quintana-Navarro G, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Mata P, Santos RD. Association of dietary components with dyslipidemia and low-grade inflammation biomarkers in adults with heterozygous familial hypercholesterolemia from different countries. Eur J Clin Nutr. 2019 Dec;73(12):1622-1625. doi: 10.1038/s41430-019-0529-3. Epub 2019 Nov 6. PMID: 31695140
- Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid. 2019 Jul 1;14:19-30. doi: 10.2147/CE.S174169. eCollection 2019. PMID: 31308834
- Pérez de Isla L, Ray KK, Watts GF, Santos RD, Alonso R, Muñiz-Grijalvo O, Diaz-Diaz JL, Badimon L, Catapano AL, Mata P. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Atherosclerosis. 2019 Jul;286:40-45. doi: 10.1016/j.atherosclerosis.2019.05.003. Epub 2019 May 4. PMID: 31100618
- Suades R, Padró T, Crespo J, Sionis A, Alonso R, Mata P, Badimon L. Liquid Biopsy of Extracellular Microvesicles Predicts Future Major Ischemic Events in Genetically Characterized Familial Hypercholesterolemia Patients. Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1172-1181. doi: 10.1161/ATVBAHA.119.312420. PMID: 31070479
- Miramontes-González JP, Usategui-Martín R, Pérez de Isla L, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Jiménez FF, Martín-Vallejo J, Rodríguez Gude AE, Jiménez DL, Padro T, González-Sarmiento R, Mata P. VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. 2019 Jun;285:17-22. doi: 10.1016/j.atherosclerosis.2019.03.019. Epub 2019 Mar 31. PMID: 30991288
- Chiva-Blanch G, Padró T, Alonso R, Crespo J, Pérez de Isla L, Mata P, Badimon L. Liquid Biopsy of Extracellular Microvesicles Maps Coronary Calcification and Atherosclerotic Plaque in Asymptomatic Patients With Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2019 May; 39(5):945-955. doi: 10.1161/ATVBAHA.118.312414. PMID: 30866660
- Ellis KL, Pérez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. J Am Coll Cardiol. 2019 Mar 12;73(9):1029-1039. doi: 10.1016/j.jacc.2018.12.037
- Arroyo-Olivares R, Alonso R, Quintana-Navarro G, Fuentes-Jiménez F, Mata N, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Arrieta F, García-Cruces J, Garrido-Sanjuan JA, Banegas JR, Mata P. Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: the SAFEHEART study. Public Health Nutr. 2019 Feb 8:1-11. doi: 10.1017/S1368980018003853.
- Pérez de Isla L, Alonso R, Mata P. Response to letter entitled «Coronary computed tomography angiogram in familial hypercholesterolemia: A double edge sword» by Dr. Sam Mirzaee and Dr. James D Cameron. J Clin Lipidol. 2018 Oct 9. pii: S1933-2874(18)30413-6. doi: 10.1016/j.jacl.2018.10.001.
- Mata P, Alonso R, Pérez de Isla L. Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all? Curr Opin Lipidol. 2018 Dec;29(6):445-452. doi: 10.1097/MOL.0000000000000553.
- Iacocca MA, Chora JR, Carrié A, Freiberger T, Leigh SE, Defesche JC, Kurtz CL, DiStefano MT, Santos RD, Humphries SE, Mata P, Jannes CE, Hooper AJ, Wilemon KA, Benlian P, O’Connor R, Garcia J, Wand H, Tichy L, Sijbrands EJ, Hegele RA, Bourbon M, Knowles JW; ClinGen FH Variant Curation Expert Panel. ClinVar database of global familial hypercholesterolemia-associated DNA variants. Hum Mutat. 2018 Nov;39(11):1631-1640. doi: 10.1002/humu.23634.
- Alonso R, Pérez de Isla L, Muñiz-Grijalvo O, Diaz-Diaz JL, Mata P. Familial Hypercholesterolaemia Diagnosis and Management. Eur Cardiol. 2018 Aug;13(1):14-20. doi: 10.15420/ecr.2018:10:2.
- Payne J, Williams S, Maxwell D, Pariente MT, Olivares RA, Janssen Ten Haaf M, Wong-Rieger D, Rieger F, Covato A, Wong-Rieger H, Cermakova L, Wilemon K. Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective. Atherosclerosis. 2018 Oct;277:377-382. doi: 10.1016/j.atherosclerosis.2018.08.020.
- EAS Familial Hypercholesterolaemia Studies Collaboration; EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators. Overview of the current status of familial hypercholesterolaemia care in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018 Oct;277:234-255. doi: 10.1016/j.atherosclerosis.2018.08.051.
- Pérez de Isla L, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Miramontes JP, Fuentes F, Gómez de Diego JJ, González-Estrada A, Mata N, Saltijeral A, Barreiro M, Tomás M, de Andrés R, Argüeso R, Serrano Gotarredona MP, Navarro Herrero S, Perea Palazón RJ, de Caralt TM, Suárez de Centi LA, Zhilina S, Espejo Pérez S, Padró T, Mata P; SAFEHEART investigators. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. J Clin Lipidol. 2018 Jul – Aug;12(4):948-957. doi: 10.1016/j.jacl.2018.04.003. Epub 2018 Apr 17.
- Sánchez Muñoz-Torrero JF, Rivas MD, Zamorano J, Joya-Vázquez PP, de Isla LP, Padro T, Mata P, The Safeheart Investigators. Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patients. Per Med. 2018 Mar;15(2):87-92. doi: 10.2217/pme-2017-0075. Epub 2018 Jan 31.
- Escate R, Mata P, Cepeda JM, Padró T, Badimon L. miR-505-3p controls chemokine receptor up-regulation in macrophages: role in familial hypercholesterolemia. FASEB J. 2018 Feb;32(2):601-612. doi: 10.1096/fj.201700476RR.
- Pérez de Isla L, Saltijeral Cerezo A, Mata P. Response by Pérez de Isla et al to Letter Regarding Article, «Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)». Circulation. 2017 Nov 14;136(20):1984. doi: 10.1161/CIRCULATIONAHA.117.030993. No abstract available.
- Villa G, Wong B, Kutikova L, Ray KK, Mata P, Bruckert E. Prediction of cardiovascular risk in patients with familial hypercholesterolaemia. Eur Heart J Qual Care Clin Outcomes. 2017 Oct 1;3(4):274-280. doi: 10.1093/ehjqcco/qcx011.
- Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti FD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Jacob Pieter Kastelein J, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P. Clinical Genetic Testing for Familial Hypercholesterolemia. JACC Scientific Expert Panel. J Am Coll Cardiol 2018:72:662-680
- Rubio-Marín P, Michán-Doña A, Maraver-Delgado J, Arroyo-Olivares R, Barrado Varea R, Pérez de Isla L, Mata P. Cascade screening program for familial hypercholesterolemia. Endocrinol Diabetes Nutr. 2018 Mar 6. pii: S2530-0164(18)30016-8. doi: 10.1016/j.endinu.2017.12.009.
- Bourbon M, Alves AC, Alonso R, Mata N, Aguiar P, Padró T, Mata P. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia. The SAFEHEART Registry. Atherosclerosis. 2017 Jul;262:8-13. doi: 10.1016/j.atherosclerosis.2017.04.002.
- Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, Saltijeral A, Fuentes-Jiménez F, de Andrés R, Zambón D, Piedecausa M, Cepeda JM, Mauri M, Galiana J, Brea Á, Sánchez Muñoz-Torrero JF, Padró T, Argueso R, Miramontes-González JP, Badimón L, Santos RD, Watts GF, Mata P. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017 May 30;135(22):2133-2144.doi: 10.1161/CIRCULATIONAHA.116.024541
- Saltijeral A, Pérez de Isla L, Alonso R, Muñiz O, Díaz-Díaz JL, Fuentes F, Mata N, de Andrés R, Díaz-Soto G, Pastor J, Pinilla JM, Zambón D, Pinto X, Badimón L, Mata P; SAFEHEART Investigators. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry. Rev Esp Cardiol (Engl Ed). 2016 Nov 29. pii: S1885-5857(16)30330-9. doi: 10.1016/j.rec.2016.10.010.
-
Lázaro P, Pérez de Isla L, Watts GF, Alonso R, Norman R, Muñiz O, Fuentes F, Mata N, López-Miranda J, González-Juanatey JR, Díaz-Díaz JL, Blasco AJ, Mata P. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017 Jan – Feb;11(1):260-271. doi: 10.1016/j.jacl.2017.01.002.
-
Santos RD, Bourbon M, Alonso R, Cuevas A, Vasques-Cardenas NA, Pereira AC, Merchan A, Alves AC, Medeiros AM, Jannes CE, Krieger JE, Schreier L, Perez de Isla L, Magaña-Torres MT, Stoll M, Mata N, Dell Oca N, Corral P, Asenjo S, Bañares VG, Reyes X, Mata P; Ibero-American Familial Hypercholesterolemia Network. Clinical and molecular factors of familial hypercholesterolemia in ibero-American countries. J Clin Lipidol. 2017 Jan – Feb;11(1):160-166. doi: 10.1016/j.jacl.2016.11.004.
-
Kindt I, Mata P, Knowles JW. The role of registries and genetic databases in familial hypercholesterolemia. Curr Opin Lipidol. 2017 Feb 6. doi: 10.1097/MOL.0000000000000398.
-
Croyal M, Fall F, Krempf M, Thédrez A, Ouguerram K, Ferchaud-Roucher V, Aguesse A, Billon-Crossouard S, Mata P, Alonso R, Lambert G, Nobécourt E. Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Feb 15;1044-1045:24-29. doi: 10.1016/j.jchromb.2016.12.040.
-
Pérez de Isla L, Saltijeral Cerezo A, Mata P. Letter by Pérez de Isla et al Regarding Article, “Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)”. Circulation. 2016 Nov 1;134(18):e393-e394.
-
Escate R, Padro T, Borrell-Pages M, Suades R, Aledo R, Mata P, Badimon L. Macrophages of genetically characterized familial hypercholesterolaemia patients show up-regulation of LDL-receptor-related proteins. J Cell Mol Med. 2016 Sep 29. doi: 10.1111/jcmm.12993.
-
Alonso R, Mata P, Muñiz O, Fuentes-Jimenez F, Díaz JL, Zambón D, Tomás M, Martin C, Moyon T, Croyal M, Thedrez A, Lambert G. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis. 2016 Nov;254:249-253. doi: 10.1016/j.atherosclerosis.2016.08.038.
-
Alonso R, Díaz-Díaz JL, Arrieta F, Fuentes-Jiménez F, de Andrés R, Saenz P, Ariceta G, Vidal-Pardo JI, Almagro F, Argueso R, Prieto-Matos P, Miramontes JP, Pintó X, Rodríguez-Urrego J, Pérez de Isla L, Mata P; Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients:Insights from SAFEHEART registry. J Clin Lipidol 2016; 10:953-961. doi: 10.1016/j.jacl.2016.04.006.
-
Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, Díaz-Díaz JL, Fuentes F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manjón L, Mauri M, Padró T, Miramontes JP, Mata P; SAFEHEART Investigators. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia. Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol. 2016;36:2004-2010. doi: 10.1161/ATVBAHA.116.307514.
-
Pérez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral A, Muñiz O, Fuentes F, Díaz-Díaz JL, de Andres R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sánchez JF, Martínez-Faedo C, Miramontes-González JP, Badimón L, Mata P; SAFEHEART Investigators. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol 2016;67:1278-85. doi: 10.1016/j.jacc.2016.01.008.
-
Fuentes F, Alcalá-Díaz JF, Watts GF, Mata P. Diabetes, statins and FH. Int J Cardiol. 2016 Jan 15;203:575. doi: 10.1016/j.ijcard.2015.10.235.
-
Wong B, Villa G, Kutikova L, Kruse G, Ray KK, Mata P, Bruckert E. The Magnitude of Increased Cardiovascular (Cv) Risk Associated with Familial Hypercholesterolemia (Fh) for use in Economic Analyses. Value Health. 2015 Nov;18(7):A340. doi: 10.1016/j.jval.2015.09.140.
-
Fuentes F, Alcala-Diaz JF, Watts GF, Alonso R, Muñiz O, Díaz-Díaz JL, Mata N, Sanchez Muñoz-Torrero JF, Brea Á, Galiana J, Figueras R, Aguado R, Piedecausa M, Cepeda JM, Vidal JI, Rodríguez-Cantalejo F, López-Miranda J, Mata P; SAFEHEART Investigators. Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. Int J Cardiol. 2015 Aug 5;201:79-84. doi: 10.1016/j.ijcard.2015.07.107.
-
Suades R, Padró T, Alonso R, Mata P, Badimon L. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. Thromb Haemost. 2015 Jul 16;114(5).
-
Ascaso JF, Mata P, Arbona C, Civeira F, Valdivielso P, Masana L. Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF). Clin Investig Arterioscler. 2015 Mar-Apr;27(2):80-96. doi: 10.1016/j.arteri.2015.01.002. Epub 2015 Mar 8.
-
Alonso R, Mata P, Alonso Y Gregorio M, de Andrés R. Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B. Med Clin (Barc). 2015 Sep 7;145(5):229-30. doi: 10.1016/j.medcli.2014.11.002. Epub 2014 Dec 24.
-
Baum SJ, Sijbrands EJ, Mata P, Watts GF. The doctor’s dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia. J Clin Lipidol. 2014 Nov-Dec;8(6):542-9. doi: 10.1016/j.jacl.2014.09.005. Epub 2014 Sep 19.
-
Mata P, Alonso R, Pérez-Jiménez F. Screening for Familial Hypercholesterolemia: a Model for Preventive Medicine. Rev Esp Cardiol. 2014 May 20. doi: 10.1016/j.recesp.2014.01.016.
-
Cubedo J, Padró T, Cinca J, Mata P, Alonso R, Badimon L. Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. Eur J Clin Invest. 2014;44:266-75.
-
Mata P, Alonso R, Ruiz A, Gonzalez-Juanatey JR, Badimón L, Díaz-Díaz JL, Muñoz MT, Muñiz O, Galve E, Irigoyen L, Fuentes-Jiménez F, Dalmau J, Pérez-Jiménez F. Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document. Aten Primaria. 2014 Apr 3. doi: 10.1016/j.aprim.2013.12.015.
-
Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P; SAFEHEART investigators. Lipoprotein(a) levels in Familial Hipercholesterolaemia: an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation. J Am Coll Cardiol. 2014; 63:1982-9.
-
Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014;171:309-25.
-
Suades R, Padró T, Alonso R, López-Miranda J, Mata P, Badimon L. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients. Thromb Haemost. 2014;111:111-21
-
.Suades R, Padró T, Alonso R, Mata P, Badimón L. Lipid-lowering therapy with statins reduces microparticles shedding from endothelium, platelets and inflammatory cells indicating protection against cell activation. Thromb Haemost 2013;110:366-77.
-
Alonso R, Mata P, Zambón D, Mata N, Fuentes Jiménez F. Early diagnosis and treatment of Familial Hypercholesterolemia: Can we improve patient outcomes. Expert Rev Cardiovasc Ther 2013; 11:327-42.
-
Nelva Mata, Rodrigo Alonso, Jose R Banegas, Daniel Zambón, Ángel Brea, Pedro Mata. Quality of life in a cohort of Familial Hypercholesterolemia patients from the south of Europe. Eur J Public Health . 2012 doi:10.1093/eurpub/cks174.
-
Aledo R, Alonso R, Mata P, Llorente-Cortés V, Padró T, Badimón L. LRP1 Gene polymorphisms are associated with premature risk of Cardiovascular Disease in patients with Familial Hypercholesterolemia. Rev Esp Cardiol 2012;65:807-812.
-
Caballero P, Alonso R, Rosado P, Mata N, Fernández-Frieras L, Jiménez-Borreguero J, Badimón L, Mata P. Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities. Atherosclerosis 2012; 222:468-72.
-
Cubedo J, Padró T, Alonso R, Cinca J, Mata P, Badimón L.Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis 2012; 222;263-9.
-
Mata M, Alonso R, Badimon L, Padró T, Fuentes F, Muñiz O, Perez-Jiménez F, López-Mirada J, Díaz JL, Vidal JI, Barba A, Piedecausa M, Sanchez JF, Irigoyen L, Guallar E, Ordovas JM, Mata P. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis 2011;10(1):94.
-
Vazquez C, Alonso R, Garriga M, de Cos A, de la Cruz JJ, Fuentes-Jiménez F, Salas- Salvadó J, Mata P. Validation of a food frequency questionnaire in Spanish patients with familial Hypercholesterolaemia. Nutr Metab Cardiovasc Dis 2012;22:836-42.
-
Criado-Garcia J, Fuentes F, Cruz-Teno C, Garcia-Rios A, Jimenez-Morales A, Delgado-Lista J, Mata P, Alonso R, Lopez-Miranda J, Perez-Jimenez F. R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study. Lipids Health Dis. 2011;10:50.
-
Garcia-Rios A, Perez-Martinez P, Mata P, Fuentes F, Lopez-Miranda J, Alonso R, Caballero J, Mata N, Perez-Jimenez F, Ordovas JM. Polymorphism at the TRIB1 gene modulates plasma lipid levels: Insight from the spanish familial hypercholesterolemia cohort study. Nutr Metab Cardiovasc Dis. 2011;21:957-63.
-
Zambón D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sánchez F, Gich J, Pocoví M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA. Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia. Am J Med 2010; 123: 267-274.
-
Garcia-Rios A, Perez-Martinez P, Fuentes F, Mata P, Lopez-Miranda J, Alonso R, Rodriguez F, Garcia-Olid A, Ruano J, Ordovas JM, Perez-Jimenez F. Genetic variations at ABCG5/G8 genes modulate plasma lipids concentrations in patients with familial hipercolesterolemia.Atherosclerosis 2010;210:486-92.
-
Alonso R, Mata N, BadimónL, Pérez-Jiménez F, Mata P. Prognostic factors of cardiovascular disease mortality and morbidity in a cohort of families with genetic diagnoses of familial Hypercholesterolemia. Nat Rev 2009;6:23-7.
Del Registro Español de Hipercolesterolemia Familiar
- Alonso R, Defesche J, Tejedor D, Castillo S, Stef M, Mata N, Gomez-Enterria P, Martinez-Faedo C, Forga L, Mata P. Genetic Diagnosis of Familial Hypercholesterolemia using a DNA-array based platform. Clin Biochem 2009;42:899-903
- Oliva J, López-Bastidas J, Gutierrez S, Mata P, Alonso R. Análisis de coste-efectividad de un programa de cribado genético en familiares directos de pacientes con hipercolesterolemia familiar en España. Rev Esp Cardiol 2009;62: 57-65.
- Alonso R, Fernández de Bobadilla J, Méndez I, Lazaro P, Mata N; Mata P. Coste-efectividad del manejo de la Hipercolesterolemia Familiar con estrategias de tratamiento preventivo basadas en atorvastatina. Rev Esp Cardiol 2008; 61: 382-93
- Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muñiz O, Galiana J, Figueras R, Díaz JL, Gómez-Enterría P, Mauri M, Piedecausa M, Irigoyen L, Aguado R, Mata P; Spanish Familial Hypercholesterolemia Group. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008; 200:315-22
- Junyent M, Gilabert R, Zambón D, Pocovi M, Mallen M, Cofan M, Nuñez I, Civeira F, Tejedro D, Ros E. Femoral Atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect. ArteriosclerThrombVasc Biol. 2008;28:580-6
- Tejedor D,Castillo S, Mozas P, Jiménez E, Lopez M, Tejedor MT, Artieda M, Alonso R, Mata P, Siomon L, Martinez A, Pocovi M. Comparison of DNA array platform vs DNA sequencing as genetic diagnosis tools for familial hypercholesterolemia. Clin Chem. 2006;52:1971-2
- Junyent M, Cofán M, Núñez I, Gilabert R, Zambón D, Ros E. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. ArteriosclerThrombVasc Biol. 2006;26:1107-13
- Merino-Ibarra E ; Castillo S, Mozas P, Cenarro A, Martorell E, Diaz JL, Suarez Tembra M, Alonso R, Civeira F, Mata P, Pocovi M. Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia.Hum Biol. 2005;77:663-73
- Civeira F, Castillo S, Alonso R, Merino-Ibarra E, Cenarro A, Artied M, Martin-Fuentes P, Ros E, Pocovi M, Mata P. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol. 2005;25:1960-5
- Tejedor D, Castillo S, Mozas P,Jiménez E, López M, Tejedor MT, Artieda M, Alonso R, Mata P, Simón L, Martínez A, Pocovi M; Spanish FH Group.. Reliable Low-Density DNA Array Based on Allele-Specific Probes for Detection of 118 Mutations Causing Familial Hypercholesterolemia Clin Chem. 2005; 51:1137-44
- Mozas P, Castillo S, Tejedor D, Reyes G, Alonso R, Franco M, Saenz P, Fuentes F, Almagro F, Mata P, Pocovi M. Molecular characterization of familial hpercholesterolemia in Spain: Identification of 39 novel and 77 recurrent mutations in LDLR. Hum Mut 2004 (#735 online).
- International panel on management of familial hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68.
- Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemai in Spain: case-finding program, clinical and genetic aspects. Sem Vasc Med 2004;1:67-74
- Mata P, Alonso R, Badimon J. Benefits and Risks of simvastatin in patients with familial hypercholesterolemia. Drug Saf 2003; 26:769-786.
- Garcia-Alvarez I, Castill S, Mozas P, Tejedor D, Reyes G, Artieda M ,et al. Diferencias en la presentación clínica en sujetos con fenotipo de hipercolesterolemia familiar por defectos en el receptor LDL y por defectos de la apo B-100. Rev Esp Cardiol 2003;56:769-74
- Mozas P, Castillo S, Reyes G, Tejedor D, Civeira F, García-Alvarez I, Puzo J, Cenarro A, Alonso R, Mata P and M. Pocoví. Apo E genotype is not associated with cardiovascular disease in heterozygous subjects with Familial Hypercholesterolemia. Am Heart J, 2003;145:999-1005
- Castillo S, Reyes G, Tejedor D, Mozas P, Suarez Y, Lasunción MA, Civeira F, Alonso R, Mata P, Pocovi M. A double mutant (2393del9+N543H) allele in the LDL-r gene in patients witj heterozygous, homozygous and compound heterozygous familial hypercholesterolemia: Effect on plasma cholesterol levels and coronary heart disease. Hum Mut 2002 (#558 online)
- Castillo S, Tejedor D, Mozas P, Reyes G, Civeira F, Alonso R, Ros E, Pocovi M, Mata P on behalf of the Spanish FH Study group. The apolipoprotein B R3500 gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis 2002;165:137-144.
- Alonso R, Castillo , Civeira F, Puzo J, de la Cruz J, Pocovi M, Mata P. Hipercolesterolemia familiar heterocigota en España. Estudio descriptivo de 819 casos no relacionados. Med Clin (Barc), 2002;118:487-92
- Mata P, Alonso R, Castillo S, Pocovi M. MEDPED and the Spanish familial hypercholesterolemia foundation. Atherosclerosis 2002;2(suppl):9-11.
Comentarios desactivados